Pregled bibliografske jedinice broj: 1059334
Review of importance specific biomarkers in laboratory medicine for patients who suffer from rheumatic arthritis
Review of importance specific biomarkers in laboratory medicine for patients who suffer from rheumatic arthritis // 2020 Book of Abstracts / Jurić, Ivana ; Pušeljić, Nora ; Švitek, Luka (ur.).
Osijek, 2020. str. 74-74 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1059334 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Review of importance specific biomarkers in
laboratory medicine for patients who suffer
from
rheumatic arthritis
Autori
Anđić Marija, Medač Petra, Čorak Daniel
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
2020 Book of Abstracts
/ Jurić, Ivana ; Pušeljić, Nora ; Švitek, Luka - Osijek, 2020, 74-74
Skup
2nd International Translational Medicine Congress of Students and Young Physicians (OSCON 2020)
Mjesto i datum
Osijek, Hrvatska, 13.02.2020. - 14.02.2020
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
RA (rheumatoid arthritis), biomarkers, YKL-40
Sažetak
Rheumatic arthritis (RA) is the most prominent systemic, chronic, progressive, the autoimmune rheumatic disease in which the immune system attacks cartilage tissue and bones, and sometimes internal organs. It is more common in women than in men. Based on the concentration of anti-carbamylate protein, it can be predicted how much the patient's joints are affected by the autoimmune disease. The results showed that MMP (matrix metalloproteinase) and YKL-40 (heparin glycoprotein and chitin) are important markers for predicting joint failure. MMP3 is significantly associated with disease activity, inflammatory mediators and cartilage breakdown, and is a potential biomarker of disease severity. Immunocytochemical study found that YKL-40 is present in polymorphonuclear cells in the synovial fluid of RA patients. The big correlation is that biomarkers will effectively and safely achieve results on the characteristics of the patient's disease and the treatment group being tested. The future tends to characterize individual profiles, therefore, with the help of genomics and proteomics, significant improvements are expected at the time of diagnosis and response to therapy.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Osijek